Patents by Inventor Haim Tsubery
Haim Tsubery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240279591Abstract: A method of producing spherical particles is provided herein. Also provided are compositions generated thereby and uses thereof in disease diagnosis and treatment.Type: ApplicationFiled: June 12, 2022Publication date: August 22, 2024Applicants: Nano Ghost Ltd, Technion Research & Development Foundation LimitedInventors: Osnat BOHANA-KASHTAN, Oded PINKAS, Irina GOTLIV, Haim TSUBERY, Tal Yoetz KOPELMAN, Neta CHAIM, Noa AVNI, Hanna LIANDRES, Roy GOVRIN, Yonatan MALCA, Marcelle MACHLUF, Orit AMSALEM-BERGELSON
-
Patent number: 9956295Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: July 22, 2016Date of Patent: May 1, 2018Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Publication number: 20160324975Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: July 22, 2016Publication date: November 10, 2016Inventors: Yoram SHECHTER, Matityahu FRIDKIN, Haim TSUBERY
-
Patent number: 9433683Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: July 10, 2015Date of Patent: September 6, 2016Assignee: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Publication number: 20160000927Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: July 10, 2015Publication date: January 7, 2016Inventors: Yoram SHECHTER, Matityahu FRIDKIN, Haim TSUBERY
-
Patent number: 9119883Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: August 26, 2014Date of Patent: September 1, 2015Assignee: Yeda Research and Development Co., Ltd.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Publication number: 20150057219Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: August 26, 2014Publication date: February 26, 2015Inventors: Yoram SHECHTER, Matityahu Fridkin, Haim Tsubery
-
Patent number: 8877709Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: January 2, 2014Date of Patent: November 4, 2014Assignee: Yeda Research and Development Co., Ltd.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Patent number: 8735350Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: December 31, 2012Date of Patent: May 27, 2014Assignee: Yeda Research and Development Co., Ltd.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Publication number: 20140121352Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: January 2, 2014Publication date: May 1, 2014Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: YORAM SHECHTER, MATITYAHU FRIDKIN, HAIM TSUBERY
-
Publication number: 20130116175Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: December 31, 2012Publication date: May 9, 2013Applicant: Yeda Research and Development Co., Ltd.Inventors: Yoram SHECHTER, Matityahu Fridkin, Haim Tsubery
-
Patent number: 8343910Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: August 12, 2009Date of Patent: January 1, 2013Assignee: Yeda Research Development Co., LtdInventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Publication number: 20110182948Abstract: The present invention relates to the use of a filamentous agent other than a filamentous bacteriophage to disaggregate aggregated proteins in plaque or to treat a patient suffering from or susceptible to a disease characterized by the presence of plaque.Type: ApplicationFiled: May 22, 2009Publication date: July 28, 2011Inventors: Beka Solomon, Oded Grinstein, Nir Friedman, Michal Arbel, Haim Tsubery, Richar Fisher
-
Publication number: 20100041867Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: August 12, 2009Publication date: February 18, 2010Applicant: Yeda Reserch and Development Co., Ltd.Inventors: Yoram SHECHTER, Matityahu Fridkin, Haim Tsubery
-
Patent number: 7585837Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: October 6, 2005Date of Patent: September 8, 2009Assignee: Yeda Research and Development Co. Ltd.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Patent number: 7435716Abstract: Novel conjugates of bacterial outer membrane binding peptides, preferably having bacterial sensitization activity, and immune cells chemotactic peptides, and pharmaceutical compositions containing same useful in the treatment of bacteremia and/or septicemia following infection by gram negative bacteria administered alone or in combination with conventional antibiotics.Type: GrantFiled: January 16, 2002Date of Patent: October 14, 2008Assignees: Ramot At Tel Aviv University Ltd., Yeda Research and Development Co. Ltd.Inventors: Itzhak Ofek, Matityahu Fridkin, Haim Tsubery
-
Publication number: 20060171920Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: October 6, 2005Publication date: August 3, 2006Applicant: Yeda Research and Development Co., Ltd.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Publication number: 20040092443Abstract: Long-acting exendin or exendin agonist derivatives of the formula (X)n-Z are provided, wherein X is a radical 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenyl-methoxycarbonyl (FMS), Z is the residue of an exendin or exendin agonist linked to the radical X through an amino or hydroxyl group, and n is 1 to 3. The exendin is exendin-3 or exendin-4. The derivatives are useful for prevention or treatment of conditions, diseases or disorders that can be treated by an exendin, for example for prevention of hyperglycemia and for treatment of diabetes mellitus, e.g. non-insulin dependent diabetes mellitus, insulin-dependent diabetes mellitus, and gestational diabetes mellitus.Type: ApplicationFiled: April 8, 2003Publication date: May 13, 2004Applicant: YEDA Research and Development Co., LtdInventors: Matityahu Fridkin, Yoram Shechter, Haim Tsubery
-
Publication number: 20040082505Abstract: Novel conjugates of bacterial outer membrane binding peptides, preferably having bacterial sensitization activity, and immune cells chemotactic peptides, and pharmaceutical compositions containing same useful in the treatment of bacteremia and/or septicemia following infection by gram negative bacteria administered alone or in combination with conventional antibiotics.Type: ApplicationFiled: July 15, 2003Publication date: April 29, 2004Inventors: Itzhak Ofek, Matityahu Fridkin, Haim Tsubery